SARCOMA

Alessandro Gronchi, MD, discusses the impact of olaratumab and other emerging agents for the treatment of sarcoma, as well as what to expect at this year’s CTOS meeting.

Alessandro Gronchi, MD, president, Connective Tissue Oncology Society (CTOS), discusses some of the exciting data that will be presented at the 21st annual CTOS meeting in Lisbon, Portugal.

A subgroup analysis from a phase III, open-label, randomized study showed that eribulin (Halaven) had comparable activity to dacarbazine (DTIC) in patients with leiomyosarcoma.

Advanced Soft Tissue Sarcoma with Brian Van Tine, MD, PhD

Advanced Soft Tissue Sarcoma with Brian Van Tine, MD, PhD

Advanced Soft Tissue Sarcoma with Mark Agulnik, MD

Advanced Soft Tissue Sarcoma with Mark Agulnik, MD

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discuses exciting advancements in the field of sarcoma.

The PDGFRα antagonist olaratumab (Lartruvo) has been granted an accelerated approval from the FDA in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS) who are not candidates for radiotherapy or surgery.

Katherine Thornton, MD, discusses the potential that immunotherapy agents could have in sarcoma, as well as the role of genomic profiling in understanding the patients who may benefit from select treatments.

A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses.

A technically negative trial in high-risk adult soft tissue sarcoma nonetheless produced a significant survival benefit for anthracycline-based neoadjuvant chemotherapy, according to a study presented at the 2016 ESMO Congress.

Lori Rink, PhD, speaks about what oncologists have learned about GIST in the past 3 decades, the important role of imatinib mesylate (Gleevec) in treating the disease, and the personalized treatment approach on the horizon.

In the past 12 months, two agents have been approved for soft tissue sarcoma, both of which have demonstrated impressive outcomes in patients with specific subtypes of the rare disease.

A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses, according to a study published in the&nbsp;<em>Journal of Clinical Oncology</em>.<br /> &nbsp;

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses how sarcoma is leading the way in the breakdown of cancers into different types.

The PDGFR&alpha; antagonist olaratumab has been recommended approval by&nbsp;The Committee for Medicinal Products for Human Use (CHMP)&nbsp;for use in combination with doxorubicin for patients with advanced soft tissue sarcoma (STS) who are not good candidates for radiotherapy or surgery.

Scientific breakthroughs can be difficult in a rare disease such as sarcoma, which makes up less than 1% of all adult cancers and comprises more than 50 subtypes.

Treatment with pembrolizumab led to a reduction of tumor size in 33% of patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

The FDA has placed a partial clinical hold on a planned pivotal trial examining NY-ESO SPEAR T-cell therapy in patients with myxoid round cell liposarcoma.

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the relevance of sarcoma in the converging worlds of targeted therapies and immuno-oncology.

Research is making only modest progress in the discovery&nbsp;of receptor tyrosine kinase inhibitors that show benefit&nbsp;in the treatment of sarcomas, Gary K. Schwartz, MD, argued during a presentation at the 2016 ASCO Annual Meeting.